Study wrapper · #1198
From Pathobiology to Prescribing in Obesity-Driven HFpEF: A Systematic Review and Practical Therapeutic Framework.
Editor's note
This is a synthesis rather than new trial data, but it is a useful marker of where cardiology consensus is heading: incretin peptides are being written into the core HFpEF playbook, not the margins. The semaglutide claims rest on the STEP-HFpEF program and the tirzepatide claims on SUMMIT, both dedicated randomized trials, so the framework stands on reasonably firm ground. The proposed sequencing itself is the authors' judgment and has not been tested head-to-head. Worth covering as a signal of how quickly these agents have moved into mainstream heart-failure thinking.
Plain-language abstract
Heart failure with preserved ejection fraction (HFpEF) is a form of heart failure that is increasingly tied to obesity. This systematic review pulled together the drug evidence for that specific patient group and proposes a practical order in which clinicians might use the available options. It places SGLT2 inhibitor pills as the foundation because they have the most mature outcome data, with semaglutide shown in dedicated trials to improve symptoms, exercise capacity, and body weight, and tirzepatide additionally reducing worsening heart-failure events. The authors argue this condition should be managed as a whole-body metabolic syndrome rather than a purely cardiac one.